Potentials of Interferon Therapy in the Treatment of XXXX .

@entity1 @entity788 @entity5 @entity2391 @entity3027
UNASSIGNED: @entity788 is a highly aggressive malignancy with limited treatment options. To improve survival for @entity1 with @entity788 , research has focused on other treatment modalities like adding biological modulators such as type-I interferons (IFNs). Type I IFNs (ie, @entity3027 / @entity2391 ) have antiproliferative, antiviral, and immunoregulatory activities. Furthermore, they are able to induce apoptosis, exert cell cycle blocking, and sensitize @entity5 cells for chemo- and radiotherapy. A few years ago in vitro, in vivo, and several clinical trials have been described regarding adjuvant @entity3027 therapy in the treatment of @entity788 . Some studies reported a remarkable increase in the 2- and 5-year survival. Unfortunately, the only randomized clinical trial did not show a significant increase in overall survival, although the increased median survival implicated that some @entity1 in the experimental group benefited from the adjuvant @entity3027 therapy. Furthermore, encouraging in vitro and in vivo data points to a possible role for adjuvant @entity3027 therapy. However, up till now, the use of IFNs in the treatment of @entity788 remains controversial. This review, therefore, aims to describe, based on the available data, whether there is a distinct role for @entity3027 therapy in the treatment of @entity788 .
